Orlistat Reverse Fatty Infiltration and Improves Hepatic Fibrosis in Obese Patients with Nonalcoholic Steatohepatitis (NASH)

Osamah Hussein; Masha Grosovski; Sorina Schlesinger; Sergio Szvalb
October 2007
Digestive Diseases & Sciences;Oct2007, Vol. 52 Issue 10, p2512
Academic Journal
Abstract  Nonalcoholic steatohepatitis (NASH) may cause progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Treatment, thus far, has been restricted to diet and weight loss, but without compelling results. In this study we aimed to evaluate the efficacy of orlistat therapy in obese patients with NASH. Fourteen obese patients with NASH underwent liver biopsy prior to and subsequent to 6 months treatment with orlistat (120 mg tid). Hepatic fat extension was graded as normal, mild, moderate, or severe. Hepatic fibrosis was scored on a scale from 0 to 4, with 0 denoting no fibrosis and 4, cirrhosis. Portal inflammation was scored as 0–3, with 0 = normal, 1 = mild, 2 = moderate, and 3 = severe inflammation. Fourteen patients had NASH associated with diabetes, hyperlipidemia, or obesity. Orlistat reduced fatty infiltration in 10 patients (70%; P


Related Articles

  • Track 8 Pharmacological treatment P260-P313.  // International Journal of Obesity & Related Metabolic Disorders;May2001 Supplement, Vol. 25, pS103 

    Presents articles related to pharmacological treatment of obesity published in the May 3, 2001 issue of the periodical 'International Journal of Obesity.' Significance of orlistat therapy in weight loss and long-term weight maintenance; Impact of orlistat therapy on weight reduction in morbid...

  • WEIGHT WATCHER. Springen, Karen // Newsweek;2/6/2006, Vol. 147 Issue 6, p70 

    This article discusses the pros and cons of taking the weight loss drug orlistat, a medication which is marketed by Roche and is sold under the name of Xenical. Orlistat is prescribed by doctors as a weight loss drug and is typically recommended only for those patients suffering from...

  • Safety profile of orlistat: results of a prescription-event monitoring study. Acharya, N. V.; Wilton, L. V.; Shakir, S. A. W. // International Journal of Obesity;Nov2006, Vol. 30 Issue 11, p1645 

    Introduction:Orlistat, the first of a new class of drugs for the treatment of obesity, was launched in the UK in December 1998. The prescribing information recommends that treatment with orlistat should be discontinued after 12 weeks if the patient has not achieved a specified loss of...

  • Effectiveness of Primary Care-Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force. LeBlanc, Erin S.; O'Connor, Elizabeth; Whitlock, Evelyn P.; Patnode, Carrie D.; Kapka, Tanya // Annals of Internal Medicine;10/4/2011, Vol. 155 Issue 7, p434 

    Background: Overweight and obesity in adults are common and adversely affect health. Purpose: To summarize effectiveness and harms of primary care- relevant weight-loss interventions for overweight and obese adults. Data Sources: MEDLINE, Cochrane Central Register of Controlled Trials, and...

  • A pharmacologic approach to obesity. Lucas, Charles P.; Segal, Karen R.; Hauptman, Jonathan // Contemporary OB/GYN;Jun2000, Vol. 45 Issue 6, p18 

    Evaluates the effectiveness of orlistat for the treatment of obesity. Gender-specific effects of obesity; Effect of orlistat on weight loss; Side effects of orlistat. INSET: Fighting obesity.

  • Poster session: Track 6, Psychological, social and economic issues.  // International Journal of Obesity & Related Metabolic Disorders;May2003 Supplement, Vol. 27, pS146 

    International Journal of Obesity (2003) 27, S146-S156. doi:10.1038/sj.ijo.0802364

  • The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach. Hertzman, Peter // PharmacoEconomics;2005, Vol. 23 Issue 10, p1007 

    Objective: To calculate the cost effectiveness (from the Swedish healthcare perspective) of orlistat plus diet for an obese and overweight population in a 1-year weight-management responder programme versus a 1-year weight-management programme based on diet only. As a reference,...

  • Press coverage and sales of Xenical in Sweden, 1998—2000. Brounéus, Fredrik; Dahlin, Anna; Beermann, Björn // European Journal of Clinical Pharmacology;Jun2005, Vol. 61 Issue 4, p285 

    Objective: The anti-obesity drug Xenical (orlistat, Roche) was launched on the Swedish market in February 1999. The sales peaked in May 1999 and then declined. The purpose of this study was to investigate the press coverage of Xenical during the period 1998–2000 and, if possible, relate...

  • Pharmacotherapy for obesity. Kyoung Kon Kim // Journal of the Korean Medical Association / Taehan Uisa Hyophoe ;Apr2011, Vol. 54 Issue 4, p409 

    Due to its serious comorbidities and high prevalence, obesity is one of the heaviest burdens for public health. Although diet, exercise and behavioral modification are the first-line treatment for obesity, their outcomes are not satisfactory. The goal of this article is to review currently...


Read the Article


Sign out of this library

Other Topics